Especially important will be work addressing the molecular basis of AML pathogenesis, from initiation to mechanisms underpinning leukemia relapse. Given the recent release of 2022 AML diagnostic and ...

Collectively, array studies have identified new clonal deletions and amplifications that probably contribute to disease pathogenesis ... and less progression to AML (p = 0.033) [11] Graubert ...

These findings warrant further exploration into the mechanisms by which SDF-1α contributes to AML pathophysiology and treatment outcomes. Moreover, prospective clinical trials are needed to validate ...

TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.

ALL = Acute lymphoblastic leukemia; AML = Acute myeloid leukemia; FTI = Farnesyltransferase inhibitor; HDAC = Histone deacetylase; NF = Nuclear factor; Ph = Philadelphia chromosome; TKI = Tyrosine ...

He was appointed by President Obama to the National Cancer Advisory Board in 2015. Ley studies the molecular pathogenesis of Acute Myeloid Leukemia (AML). He and his colleagues sequenced the first ...

How is acute myeloid leukemia (AML) treated? The main treatment for most types of AML is chemotherapy, sometimes along with a targeted therapy drug. This might be followed by a stem cell transplant.